Cargando…
Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation
(1) Background: Cryoballoon pulmonary vein isolation (cryoPVI) is established for symptomatic paroxysmal atrial fibrillation (AF) treatment, but its value in persistent AF is less clear. In particular, limited data are available on its efficacy in elderly patients (≥75 years) with persistent AF. Age...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604667/ https://www.ncbi.nlm.nih.gov/pubmed/36294392 http://dx.doi.org/10.3390/jcm11206070 |
_version_ | 1784817872011264000 |
---|---|
author | Boehmer, Andreas A. Rothe, Moritz Zezyk, Celine Soether, Christina M. Dobre, Bianca C. Kaess, Bernhard M. Ehrlich, Joachim R. |
author_facet | Boehmer, Andreas A. Rothe, Moritz Zezyk, Celine Soether, Christina M. Dobre, Bianca C. Kaess, Bernhard M. Ehrlich, Joachim R. |
author_sort | Boehmer, Andreas A. |
collection | PubMed |
description | (1) Background: Cryoballoon pulmonary vein isolation (cryoPVI) is established for symptomatic paroxysmal atrial fibrillation (AF) treatment, but its value in persistent AF is less clear. In particular, limited data are available on its efficacy in elderly patients (≥75 years) with persistent AF. Age is an important modifier of AF progression and represents a risk-factor for AF recurrence. (2) Methods: Prospective, single-center observational study to evaluate the impact of age on efficacy and safety of cryoPVI in elderly patients. Primary efficacy endpoint was symptomatic AF recurrence after 90-day blanking period. Primary safety endpoints were death from any cause, procedure-associated complications or stroke/transient ischemic attack. Median follow-up was 17 months (range 3–24). (3) Results: We included 268 patients with persistent AF (94 ≥ 75 years of age). Multivariate Cox regression analysis identified age as the only independent factor influencing AF recurrence in the overall cohort (p = 0.006). To minimize confounding bias in efficacy and safety analysis of cryoPVI, we matched younger and elderly patients with respect to baseline characteristics. At 24 months, primary efficacy endpoint occurred in 13/69 patients <75 years and 31/69 patients ≥75 years of age (24 months Kaplan–Meier event-rate estimates, HR 0.34; 95% CI, 0.19 to 0.62; log-rank p = 0.0004). No differences were observed in the occurrence of safety end points. (4) Conclusions: Elderly (≥75 years) patients with persistent AF undergoing cryoPVI had an approximately threefold higher risk of symptomatic AF recurrence than matched younger patients. Accordingly, other treatment modalities may be evaluated in this population. |
format | Online Article Text |
id | pubmed-9604667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96046672022-10-27 Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation Boehmer, Andreas A. Rothe, Moritz Zezyk, Celine Soether, Christina M. Dobre, Bianca C. Kaess, Bernhard M. Ehrlich, Joachim R. J Clin Med Article (1) Background: Cryoballoon pulmonary vein isolation (cryoPVI) is established for symptomatic paroxysmal atrial fibrillation (AF) treatment, but its value in persistent AF is less clear. In particular, limited data are available on its efficacy in elderly patients (≥75 years) with persistent AF. Age is an important modifier of AF progression and represents a risk-factor for AF recurrence. (2) Methods: Prospective, single-center observational study to evaluate the impact of age on efficacy and safety of cryoPVI in elderly patients. Primary efficacy endpoint was symptomatic AF recurrence after 90-day blanking period. Primary safety endpoints were death from any cause, procedure-associated complications or stroke/transient ischemic attack. Median follow-up was 17 months (range 3–24). (3) Results: We included 268 patients with persistent AF (94 ≥ 75 years of age). Multivariate Cox regression analysis identified age as the only independent factor influencing AF recurrence in the overall cohort (p = 0.006). To minimize confounding bias in efficacy and safety analysis of cryoPVI, we matched younger and elderly patients with respect to baseline characteristics. At 24 months, primary efficacy endpoint occurred in 13/69 patients <75 years and 31/69 patients ≥75 years of age (24 months Kaplan–Meier event-rate estimates, HR 0.34; 95% CI, 0.19 to 0.62; log-rank p = 0.0004). No differences were observed in the occurrence of safety end points. (4) Conclusions: Elderly (≥75 years) patients with persistent AF undergoing cryoPVI had an approximately threefold higher risk of symptomatic AF recurrence than matched younger patients. Accordingly, other treatment modalities may be evaluated in this population. MDPI 2022-10-14 /pmc/articles/PMC9604667/ /pubmed/36294392 http://dx.doi.org/10.3390/jcm11206070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Boehmer, Andreas A. Rothe, Moritz Zezyk, Celine Soether, Christina M. Dobre, Bianca C. Kaess, Bernhard M. Ehrlich, Joachim R. Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation |
title | Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation |
title_full | Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation |
title_fullStr | Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation |
title_full_unstemmed | Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation |
title_short | Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation |
title_sort | persistent atrial fibrillation in elderly patients: limited efficacy of pulmonary vein isolation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604667/ https://www.ncbi.nlm.nih.gov/pubmed/36294392 http://dx.doi.org/10.3390/jcm11206070 |
work_keys_str_mv | AT boehmerandreasa persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation AT rothemoritz persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation AT zezykceline persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation AT soetherchristinam persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation AT dobrebiancac persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation AT kaessbernhardm persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation AT ehrlichjoachimr persistentatrialfibrillationinelderlypatientslimitedefficacyofpulmonaryveinisolation |